Vashi VI - Search Results

1

Pharmacokinetics of ampicillin and sulbactam in pediatric patients.

Nahata MC, Vashi VI, Swanson RN, Messig MA, Chung M. Nahata MC, et al. Among authors: vashi vi. Antimicrob Agents Chemother. 1999 May;43(5):1225-9. doi: 10.1128/AAC.43.5.1225. Antimicrob Agents Chemother. 1999. PMID: 10223940 Free PMC article. Clinical Trial.

2

Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers.

Vashi V, Chung M, Dias N, Phillips K. Vashi V, et al. J Clin Pharmacol. 1996 Apr;36(4):325-31. doi: 10.1002/j.1552-4604.1996.tb04208.x. J Clin Pharmacol. 1996. PMID: 8728346 Clinical Trial.

3

Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.

Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Chung M, et al. Br J Clin Pharmacol. 1999 Nov;48(5):678-87. doi: 10.1046/j.1365-2125.1999.00067.x. Br J Clin Pharmacol. 1999. PMID: 10594469 Free PMC article. Clinical Trial.

4

The effects of hepatic impairment on the pharmacokinetics of doxazosin.

Penenberg D, Chung M, Walmsley P, Vashi V. Penenberg D, et al. J Clin Pharmacol. 2000 Jan;40(1):67-73. doi: 10.1177/00912700022008711. J Clin Pharmacol. 2000. PMID: 10631624 Clinical Trial.

5

Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group.

Fawzy A, Vashi V, Chung M, Dias N, Gaffney M. Fawzy A, et al. Urology. 1999 Feb;53(2):329-35. doi: 10.1016/s0090-4295(98)00506-8. Urology. 1999. PMID: 9933049 Clinical Trial.

6

Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.

Vashi V, Chung M, Hilbert J, Lawrence V, Phillips K. Vashi V, et al. J Clin Pharmacol. 1998 Nov;38(11):1072-6. doi: 10.1177/009127009803801113. J Clin Pharmacol. 1998. PMID: 9824790 Clinical Trial.

7

Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules.

Vashi V, Harris S, El-Tahtawy A, Wu D, Cipriano A. Vashi V, et al. J Clin Pharmacol. 2005 May;45(5):547-54. doi: 10.1177/0091270005274552. J Clin Pharmacol. 2005. PMID: 15831778 Clinical Trial.

8

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.

Zhou J, Limsakun T, Yin O, Warren V, Zamora C, Atiee G, Kochan J, Pav J, Kobayashi F, Vashi V, Dishy V. Zhou J, et al. J Clin Pharmacol. 2019 Dec;59(12):1669-1677. doi: 10.1002/jcph.1474. Epub 2019 Jun 27. J Clin Pharmacol. 2019. PMID: 31243790 Clinical Trial.

9

Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects.

Maekawa Y, Furuie H, Kato M, Myobatake Y, Kamiyama E, Watanabe A, Shiosakai K, Taguchi T, Bass R, Zhou J, Dishy V, Warren V, Vashi V, Ishizuka H. Maekawa Y, et al. Clin Drug Investig. 2019 Oct;39(10):967-978. doi: 10.1007/s40261-019-00825-1. Clin Drug Investig. 2019. PMID: 31321631 Clinical Trial.

10

Effect of pH on the in vitro dissolution and in vivo absorption of controlled-release theophylline in dogs.

Vashi VI, Meyer MC. Vashi VI, et al. J Pharm Sci. 1988 Sep;77(9):760-4. doi: 10.1002/jps.2600770908. J Pharm Sci. 1988. PMID: 3225770

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters